These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23367680)

  • 21. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.
    Pinkawa M; Fischedick K; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Urology; 2006 Jul; 68(1):104-9. PubMed ID: 16806434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
    Barrass BJ; Thurairaja R; Persad RA
    BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
    Lycette JL; Bland LB; Garzotto M; Beer TM
    Clin Genitourin Cancer; 2006 Dec; 5(3):198-205. PubMed ID: 17239273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [When to begin with androgen deprivation?].
    Bex A; Rübben H
    Urologe A; 1998 Mar; 37(2):133-4. PubMed ID: 9563119
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
    Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonsteroidal anti-androgens: role in treating advanced prostate cancer.
    Newton M; Kosier JH
    Urol Nurs; 1998 Mar; 18(1):56-7, 83. PubMed ID: 9582897
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Hara et al.: Decline of the red cell blood count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor 1 and erythropoesis. (Urology 2010;75:1441-1445).
    Colloca G; Venturino A; Vitucci P
    Urology; 2010 Oct; 76(4):1020. PubMed ID: 20932425
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Common stem--lutamide.
    Prescrire Int; 2014 Oct; 23(153):236. PubMed ID: 25964967
    [No Abstract]   [Full Text] [Related]  

  • 34. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 36. The 'flare' phenomenon: should we be concerned?
    Thurairaja R; Persad R; Peters J; Bahl A
    BJU Int; 2005 Jul; 96(1):4-6. PubMed ID: 15963110
    [No Abstract]   [Full Text] [Related]  

  • 37. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
    Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
    BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.